Study Finds Link Between Phase-III Genitourinary Oncology Trial Endpoint Fulfillment and FDA Approval Probability

Strategic Insights -

A new study has investigated the impact of Phase-III genitourinary oncology trial endpoint fulfillment (EF+) on FDA approval probability over the past 15 years. Research published in Clinical Genitourinary Cancer found that trials with overall survival EF+ (OS+) had a significantly higher likelihood of FDA approval. The study analyzed 183 trials, with 78 (42.6%) meeting inclusion criteria, and found that FDA approval was granted in 40/78 trials. The research concluded that OS+ significantly increased approval likelihood, with a hazard ratio of 8.38 (95% CI, 4.1-17.1, P < 0.001). These findings can guide future trial designs to optimize regulatory success in GU oncology.

Key Takeaways:

  • The study investigated the impact of Phase-III genitourinary oncology trial endpoint fulfillment (EF+) on FDA approval probability over the past 15 years.
  • Trials with overall survival EF+ (OS+) had a significantly higher likelihood of FDA approval, with a hazard ratio of 8.38 (95% CI, 4.1-17.1, P < 0.001).
  • The study analyzed 183 trials, with 78 (42.6%) meeting inclusion criteria, and found that FDA approval was granted in 40/78 trials.
  • The research concluded that OS+ significantly increased approval likelihood and can guide future trial designs to optimize regulatory success in GU oncology.
  • The study's findings are based on data from ClinicalTrials.gov and include urothelial/bladder cancer (UCa), renal cancer (RCa), and prostate cancer (PCa) trials.
  • The research was conducted at the University of Rochester Medical Center and included a team of authors led by Matthew Steidle of the Dept. of Urology.

Statistics:

  • Hazard ratio of 8.38 (95% CI, 4.1-17.1, P < 0.001) indicating significantly increased approval likelihood for trials with OS+.
  • 78 (42.6%) of 183 trials met inclusion criteria.
  • 40/78 trials received FDA approval.
  • 183 trials were screened, with 78 meeting inclusion criteria.
  • The study analyzed trials over a 15-year period (from 2010 to 2024).

Sources:

  • NewsRx. Reports from University of Rochester Medical Center Provide New Insights into Cancer (Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies). Cancer Weekly. October 28, 2025; p 702.
  • Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies. Clinical Genitourinary Cancer, 2025;23(6):102436.